Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo

Breast cancer (BC) is the most frequently diagnosed female cancer and second leading cause of death. Despite the discovery of many antineoplastic drugs for BC, the current therapy is not totally efficient. In this study, we investigated the potential of repurposing the well-known diabetes type II dr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Chemico-biological interactions Jg. 349; S. 109641
Hauptverfasser:	Chequin, Andressa, Costa, Luiz E., de Campos, Felipe F., Moncada, Angie D.B., de Lima, Lucas T.F., Sledz, Lucas R., Picheth, Guilherme F., Adami, Eliana R., Acco, Alexandra, Gonçalves, Marcos B., Manica, Graciele C.M., Valdameri, Gláucio, de Noronha, Lucia, Telles, José E.Q., Jandrey, Elisa H.F., Costa, Erico T., Costa, Fabricio F., de Souza, Emanuel M., Ramos, Edneia A.S., Klassen, Giseli
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Elsevier B.V 01.11.2021
Schlagworte:	Breast cancer DNA methylation DNMT1 Drug repurposing Epigenetics Liraglutide Epigenetics DNA methylation Drug repurposing DNMT1 Breast cancer Liraglutide
ISSN:	0009-2797, 1872-7786, 1872-7786
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!